Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 18Genitourinary 8Gynecologic 7Breast 7Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Sarcoma 9Osteosarcoma 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Neuroblastoma 3Neoplasms 3Medulloblastoma 3Glioma 3Ependymoma 3Central Nervous System Neoplasms 3Carcinosarcoma 3Wilms Tumor 2Rhabdoid Tumor 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Endometrial Neoplasms 2Carcinoma, Endometrioid 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Prostatic Neoplasms 1Pheochromocytoma 1Pathologic Complete Response 1

Interventions

Gemcitabine 9pembrolizumab 7Irinotecan 5Docetaxel 4Cisplatin 4Carboplatin 4Capecitabine 4Albumin-Bound Paclitaxel 4Paclitaxel 3Oxaliplatin 3Leucovorin 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3pazopanib 2palbociclib 2liposomal doxorubicin 2entrectinib 2alectinib 2Vinorelbine 2Trastuzumab 2Taxes 2Radiosurgery 2Oncolytic Virotherapy 2Observation 2Ipilimumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × olaparib × Sarcoma × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡